- Home
- SPT vs PBYI Comparison
SPT vs PBYI Comparison
Compare SPT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPT | PBYI |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.7M | 413.3M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SPT | PBYI |
|---|---|---|
| Price | $10.07 | $9.11 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $11.75 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 282.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | ★ $457,547,000.00 | $27,685,000.00 |
| Revenue This Year | $8.86 | N/A |
| Revenue Next Year | $8.04 | N/A |
| P/E Ratio | ★ N/A | $118.63 |
| Revenue Growth | ★ 12.72 | N/A |
| 52 Week Low | $4.92 | $4.30 |
| 52 Week High | $16.03 | $9.51 |
Technical Indicators
Market Signals| Indicator | SPT | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 62.45 |
| Support Level | $9.19 | $7.44 |
| Resistance Level | $10.56 | $9.40 |
| Average True Range (ATR) | 0.49 | 0.44 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 82.41 | 82.86 |
Price Performance
Historical ComparisonAbout SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.